Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: A nationwide cohort study

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Lee, Chih Hsin ^a,b,c   Lee, Ming Chia ^b   Shu, Chin Chung ^d   Lim, Chor Shen ^b   Wang, Jann Yuan ^d   Lee, Li Na ^d   Chao, Kun Mao ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chronic obstructive pulmonary disease; Inhaled corticosteroid; Oral corticosteroid; Time dependent cox regression; Tuberculosis

Indexed keywords

AMINOPHYLLINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGE; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MEGADOSE; FEMALE; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; LOWEST INCOME GROUP; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; SEX DIFFERENCE; TAIWAN;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; TAIWAN; TUBERCULOSIS, PULMONARY;

EID: 84876806383     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-194     Document Type: Article

References (44)

1. World Health Organization Global Tuberculosis Report. Book Global Tuberculosis Report 2012, City: World Health Organization, World Health Organization.
2. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008, 300:423-430.
3. Oeltmann JE, Kammerer JS, Pevzner ES, Moonan PK. Tuberculosis and substance abuse in the United States, 1997-2006. Arch Intern Med 2009, 169:189-197.
4. Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis 2006, 42:1592-1595.
5. Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003, 16:38-44.
6. Ludvigsson JF, Wahlstrom J, Grunewald J, Ekbom A, Montgomery SM. Coeliac disease and risk of tuberculosis: a population based cohort study. Thorax 2007, 62:23-28.
7. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006, 55:19-26.
8. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
9. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-750.
10. Schirnhofer L, Lamprecht B, Vollmer WM, Allison MJ, Studnicka M, Jensen RL, Buist AS. COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest 2007, 131:29-36.
11. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006, 28:523-532.
12. Menezes AM, Perez-Padilla R, Hallal PC, Jardim JR, Muino A, Lopez MV, Valdivia G, Pertuze J, Montes de Oca M, Talamo C. Worldwide burden of COPD in high- and low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study. Int J Tuberc Lung Dis 2008, 12:709-712.
13. Ko FW, Hui DS, Lai CK. Worldwide burden of COPD in high- and low-income countries. Part III. Asia-Pacific studies. Int J Tuberc Lung Dis 2008, 12:713-717.
14. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19-26.
15. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Eng J Med 2007, 356:775-789.
16. Shu CC, Wu HD, Yu MC, Wang JT, Lee CH, Wang HC, Wang JY, Lee LN, Yu CJ, Yang PC, Taiwan Anti-Mycobacteria Investigation G Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine 2010, 89:53-61. Taiwan Anti-Mycobacteria Investigation G.
17. Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011, 183:675-678.
18. The National Health Insurance Statistics http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu_id=296&webdata_id=1942&WD_ID=296].
19. Lee CH, Lee MC, Lin HH, Shu CC, Wang JY, Lee LN, Chao KM. Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease. PLoS One 2012, 7:e37978.
20. Taiwan Guidelines for TB Diagnosis and Treatment 2011, Taipei, Taiwan: Centers for Disease Control, R.O.C. (Taiwan), Luh K-T, 4.
21. National Committee for Clinical Laboratory Standards (NCCLS) Antimycobacterial susceptibility testing for Mycobacterium tuberculosis: tentative standard. NCCLS document M24-T 1995, Villanova, PA: NCCLS.
22. WHO Collaborating Centre for Drug Statistics Methodology Guidelines for ATC classification and DDD assignment 2011, 14, WHO Collaborating Centre for Drug Statistics Methodology.
23. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31:143-178.
24. COPD prevalence in 12 Asia-Pacific countries and regions projections based on the COPD prevalence estimation model. Respirology 2003, 8:192-198. COPD prevalence in 12 Asia-Pacific countries and regions.
25. Wu CF, Feng NH, Chong IW, Wu KY, Lee CH, Hwang JJ, Huang CT, Lee CY, Chou ST, Christiani DC, Wu MT. Second-hand smoke and chronic bronchitis in Taiwanese women: a health-care based study. BMC Public Health 2010, 10:44.
26. Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet 2003, 362:1053-1061.
27. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, Mapp CE, Fabbri LM, Donner CF, Saetta M. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998, 158:1277-1285.
28. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456.
29. Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology 2009, 116:652-657.
30. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999, 159:941-955.
31. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Eng J Med 2001, 345:941-947.
32. Schleimer RP. Glucocorticoids suppress inflammation but spare innate immune responses in airway epithelium. Proc Am Thorac Soc 2004, 1:222-230.
33. Wang PH, Wang HC, Cheng PW, Cheng SL, Tsai CC. Hoarseness in asthmatic patients: the side effect of inhaled steroid or not?. J Asthma 2007, 44:823-826.
34. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999, 354:456-460.
35. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease, Department of Veterans Affairs Cooperative Study Group. N Eng J Med 1999, 340:1941-1947.
36. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, Rouleau M, Boukhana M, Martinot JB, Duroux P. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002, 165:698-703.
37. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J 2007, 29:660-667.
38. Bock NN, Sotir MJ, Parrott PL, Blumberg HM. Nosocomial tuberculosis exposure in an outpatient setting: evaluation of patients exposed to healthcare providers with tuberculosis. Infect Control Hosp Epidemiol 1999, 20:421-425.
39. Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income countries: a systematic review. PLoS Med 2006, 3:e494.
40. Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis 2012, 54:818-825.
41. Baijal R, Praveenkumar HR, Amarapurkar DN, Nagaraj K, Jain M. Prevalence of tuberculosis in patients with cirrhosis of liver in western India. Trop Doct 2010, 40:163-164.
42. Lin HH, Ezzati M, Chang HY, Murray M. Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med 2009, 180:475-480.
43. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009, 374:733-743.
44. Ehrlich RI, White N, Norman R, Laubscher R, Steyn K, Lombard C, Bradshaw D. Predictors of chronic bronchitis in South African adults. Int J Tuberc Lung Dis 2004, 8:369-376.